Research Article
Evaluation of the Prevalence of Chronic Kidney Disease and Rates of Oral Antidiabetic Prescribing in Accordance with Guidelines and Manufacturer Recommendations in Type 2 Diabetic Patients within a Long-Term Care Setting
Table 2
List of OADs mentioned in the NKF guidelines.
| ||||||||||||||||||||
DPP-4: Dipeptidyl peptidase inhibitor-4 ‡Saxagliptin and linagliptin were not included in the NKF guideline. They were included in the PI concordance assessment. |